Dosing Intervals of Opioid Medication for Chronic Pain

2019-10-24 12:49:46 | BioPortfolio


This study is to determine the feasibility of an n-of-1, randomized, double blind, placebo controlled case series to examine effects of extended release opioids when used at intervals shorter than recommended by the manufacturer by people with chronic pain.

Study Design


Chronic Pain


Extended Release Opioid Formulation, Shortened Intervals, Extended Release Opioid Formulation, Standard intervals, Placebo oral tablet


University Health Network
M5G 2A2




University Health Network, Toronto

Results (where available)

View Results


Published on BioPortfolio: 2019-10-24T12:49:46-0400

Clinical Trials [4113 Associated Clinical Trials listed on BioPortfolio]

Phase 3 Study to Evaluate Efficacy and Safety of Oxcarbazepine Extended-Release in Subjects With Refractory Partial Seizures Due to Epilepsy When Used With up to 3 Other Antiepileptic Drugs.

It is hypothesized that reducing the frequency of dosing may increase subject compliance and providing the drug in an extended-release formulation may alleviate some of the side effects ob...

Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)

This study will assess the food-effect bioavailability of an extended release formulation of phenylephrine HCl and its bioequivalence to the marketed immediate release phenylephrine HCl pr...

Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet

To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules foll...

Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.

PubMed Articles [8828 Associated PubMed Articles listed on BioPortfolio]

Medical Use of Long-term Extended-release Opioid Analgesics in Commercially Insured Adults in the United States.

We examined the proportion of patients initiating extended-release (ER) opioids who become long-term users and describe how pain-related diagnoses before initiation of opioid therapy vary between drug...

Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial.

Opioid maintenance treatment (OMT) is highly available in Norway, but only 50% of opioid-dependent individuals are enrolled in such programs. This study was aimed at examining if availability of exten...

Budget Impact Analysis of Extended-Release Phenytoin Capsules Compared With Immediate-Release Phenytoin Capsules for Epilepsy Patients in Thailand.

There was higher frequency of breakthrough seizures during immediate-release phenytoin capsule usage than during extended-release phenytoin capsule usage by epilepsy patients. This study aimed to esti...

Modelling the potential impact of abuse-deterrent opioids on medical resource utilization.

To extend a previously published manuscript on a model for estimating potential avoided medical events and cost savings in the United States associated with the introduction of extended-release abuse-...

Exposure-Response Analyses of Upadacitinib Efficacy in Phase 2 Trials in Rheumatoid Arthritis and Basis for Phase 3 Dose Selection.

The relationships between upadacitinib, an oral selective Janus Kinase 1 inhibitor, plasma exposures and its efficacy (assessed by ACR20/50/70 responses over time) in moderate-to severe active rheumat...

Medical and Biotech [MESH] Definitions

Hydrophilic contact lenses worn for an extended period or permanently.

A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21)

A malpresentation of the FETUS at near term or during OBSTETRIC LABOR with the fetal cephalic pole in the fundus of the UTERUS. There are three types of breech: the complete breech with flexed hips and knees; the incomplete breech with one or both hips partially or fully extended; the frank breech with flexed hips and extended knees.

A hypothalamic tripeptide, enzymatic degradation product of OXYTOCIN, that inhibits the release of MELANOCYTE-STIMULATING HORMONES.

A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).

More From BioPortfolio on "Dosing Intervals of Opioid Medication for Chronic Pain"

Quick Search

Relevant Topics

Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...

Searches Linking to this Trial